WINT / Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress

WARRINGTON, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology more_horizontal

Windtree Therapeutics (NASDAQ: WINT ) stock is falling on Thursday after the company announced the departure of its Chairman of the Board of Directors more_horizontal

On an otherwise bearish day in the markets, many investors may be looking for some good news. For those on such a search, taking a look at some of the more_horizontal

Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Ra more_horizontal

Windtree Therapeutics Inc (NASDAQ: WINT) announced results from its Phase 2 study of lucinactant (KL4 surfactant) for severe COVID-19 associated ac more_horizontal

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused o more_horizontal

Windtree Therapeutics Inc WINT has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respirato more_horizontal

Windtree Therapeutics Inc WINT has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respirato more_horizontal